Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Ronan Swords

Showing results (41-50 of 59) with videos related to

Pageof 6
Sort By:
Leukemia|July 31, 2023
Prognostic impact of secondary versus de novo ontogeny in acute myeloid leukemia is accounted for by the European LeukemiaNet 2022 risk classificationMichael J Hochman, Megan Othus, Robert P Hasserjian, et al.
Journal of Cellular and Molecular Medicine|July 9, 2009
Autophagy inhibition enhances vorinostat-induced apoptosis via ubiquitinated protein accumulationJennifer S Carew, Ernest C Medina, Juan A Esquivel, et al.
NPJ Precision Oncology|July 2, 2025
Functional cure with single agent olutasidenib in relapsed IDH1/NPM1 co-mutated AMLJustin Watts, Tiffany Nong, Katarina Micin, et al.
Blood|November 1, 2024
Refined ELN 2024 risk stratification improves survival prognostication following venetoclax-based therapy in AMLCurtis A Lachowiez, Vishvaas I Ravikumar, Jad Othman, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|December 24, 2009
Vorinostat enhances the activity of temsirolimus in renal cell carcinoma through suppression of survivin levelsDevalingam Mahalingam, Ernest C Medina, Juan A Esquivel, et al.
Leukemia & Lymphoma|March 8, 2022
Adult acute myeloid leukemia patients with <i>NUP98</i> rearrangement have frequent cryptic translocations and unfavorable outcomeWei Xie, Philipp W Raess, Jennifer Dunlap, et al.
Blood|July 24, 2010
Heat shock protein 90 regulates the expression of Wilms tumor 1 protein in myeloid leukemiasHima Bansal, Sanjay Bansal, Manjeet Rao, et al.
Molecular Oncology|October 7, 2015
p53-based strategy to reduce hematological toxicity of chemotherapy: A proof of principle studyChul S Ha, Joel E Michalek, Richard Elledge, et al.
Blood Advances|November 28, 2022
Comparison and validation of the 2022 European LeukemiaNet guidelines in acute myeloid leukemiaCurtis A Lachowiez, Nicola Long, Jennifer Saultz, et al.
Blood Neoplasia|January 5, 2026
Safety of gemtuzumab ozogamicin with cytarabine, daunorubicin, and midostaurin induction in FLT3-mutated AMLJayanshu Jain, Kelly Pugh, Shivani Handa, et al.
Pageof 6

Showing results (41-50 of 59) with videos related to

Sort By:
Pageof 6
Leukemia|July 31, 2023
Prognostic impact of secondary versus de novo ontogeny in acute myeloid leukemia is accounted for by the European LeukemiaNet 2022 risk classificationMichael J Hochman, Megan Othus, Robert P Hasserjian, et al.
Journal of Cellular and Molecular Medicine|July 9, 2009
Autophagy inhibition enhances vorinostat-induced apoptosis via ubiquitinated protein accumulationJennifer S Carew, Ernest C Medina, Juan A Esquivel, et al.
NPJ Precision Oncology|July 2, 2025
Functional cure with single agent olutasidenib in relapsed IDH1/NPM1 co-mutated AMLJustin Watts, Tiffany Nong, Katarina Micin, et al.
Blood|November 1, 2024
Refined ELN 2024 risk stratification improves survival prognostication following venetoclax-based therapy in AMLCurtis A Lachowiez, Vishvaas I Ravikumar, Jad Othman, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|December 24, 2009
Vorinostat enhances the activity of temsirolimus in renal cell carcinoma through suppression of survivin levelsDevalingam Mahalingam, Ernest C Medina, Juan A Esquivel, et al.
Leukemia & Lymphoma|March 8, 2022
Adult acute myeloid leukemia patients with <i>NUP98</i> rearrangement have frequent cryptic translocations and unfavorable outcomeWei Xie, Philipp W Raess, Jennifer Dunlap, et al.
Blood|July 24, 2010
Heat shock protein 90 regulates the expression of Wilms tumor 1 protein in myeloid leukemiasHima Bansal, Sanjay Bansal, Manjeet Rao, et al.
Molecular Oncology|October 7, 2015
p53-based strategy to reduce hematological toxicity of chemotherapy: A proof of principle studyChul S Ha, Joel E Michalek, Richard Elledge, et al.
Blood Advances|November 28, 2022
Comparison and validation of the 2022 European LeukemiaNet guidelines in acute myeloid leukemiaCurtis A Lachowiez, Nicola Long, Jennifer Saultz, et al.
Blood Neoplasia|January 5, 2026
Safety of gemtuzumab ozogamicin with cytarabine, daunorubicin, and midostaurin induction in FLT3-mutated AMLJayanshu Jain, Kelly Pugh, Shivani Handa, et al.
Pageof 6